What diseases does Imetelstat treat?

Imetelstat is a breakthrough drug primarily used to treat a specific blood disorder called myelodysplastic syndrome (MDS). MDS is a group of diseases originating from hematopoietic stem cells. Its main characteristics are abnormal bone marrow hematopoiesis and abnormal blood cell development, which can lead to refractory blood cell reduction, hematopoietic failure and other problems. Especially in patients with low-risk and intermediate-1 risk MDS, Imetelstat has demonstrated significant therapeutic effects.

This type of MDS patients often require regular red blood cell transfusions to maintain normal hemoglobin levels, especially those who have no or diminished response to traditional erythropoietin (ESA) therapy. As a telomerase inhibitor, Imetelstat has a unique mechanism of action. It can prevent the proliferation of cancer cells and abnormal bone marrow cells by inhibiting the activity of telomerase, thereby hopefully delaying or reversing the progression of MDS.

In clinical trials,Imetelstat showed impressive efficacy. For example, in the IMerge phase 3 clinical trial, patients treated with imetelstat showed a significant improvement in red blood cell transfusion independence (RBC-TI) compared with the placebo group. Specifically, at weeks 8 and 24 of treatment, patients in the imetelstat group had significantly higher RBC-TI rates than those in the placebo group, demonstrating the drug's effectiveness in reducing red blood cell transfusion dependence.

In addition,Imetelstat also demonstrates good security. Although some adverse reactions may occur during use, such as thrombocytopenia and neutropenia, etc., these are controllable and can be effectively managed under the guidance of a doctor.

In summary,Imetelstat provides a new treatment option for MDS patients, especially those who do not respond to traditional ESA treatment. Its unique mechanism of action and significant therapeutic effect make Imetelstat a new choice in the treatment of blood diseases.